Tools and Guidelines

Displaying results 1 - 10 of 404

Resource | Guidelines
This guidelines is an updated version of the pervious “National Consolidated Guidelines on Strategic Information of HIV Response in Nepal 2016-2021”. This guidelines has been updated to serve for monitoring the priorities set by NHSP 2021-2026 and is inline with international and national strategies and plans. With restructuring of the country, the SI system should also address all three tiers of health governanace. This guidelines has aimed to become a hands-on document, with organizational/project system and other emerging issues incorporated.
 
 
Resource | Guidelines
The objective of the guidelines is to provide updated, evidence-informed clinical and practical recommendations on case management of people with symptoms of STI. The national guidelines recommend a syndromic approach for the management of the STI.  
 
 
Resource | Guidelines
Hepatitis C virus (HCV) infection is a major public health problem and cause of chronic liver disease that leads to approximately 399 000 deaths annually. In 2019, only 21% of the 58 million persons with chronic HCV infection had been diagnosed, and 13%, treated. These guidelines provide updated evidence-based recommendations on the priority HCV-related topics from the 2018 WHO Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C infection and the 2017 WHO Guidelines on hepatitis B and C testing.
 
 
Resource | Guidelines
National Guideline on HIV testing and treatment 2022 introduces new standards for viral load testing and viral load suppression. The guidelines also stress on community-based care of PLHIV with differentiated care approach which means less hospital visits for healthy PLHIV and more time to provide for critical patients.
 
 
Resource | Guidelines
The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatment of TB meningitis, the use of bedaquiline and delamanid in young children with multidrug- and rifampicin-resistant TB and decentralized and family-centred, integrated models of care for TB case detection and prevention in children and adolescents.
 
 
Resource | Guidelines
The “WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis – Tests for tuberculosis infection” is a new consolidated policy guideline on tests for TB infection. The policy includes, for the first-time recommendations on a new class of Mycobacterium tuberculosis antigen-based skin tests (TBSTs) and consolidates all currently existing recommendations for the diagnosis of TB infection, including the traditional tuberculin skin test (TST) and interferon-gamma release assays (IGRAs). IGRAs and TBSTs use Mycobacterium tuberculosis complex specific antigens and represent a significant advancement to TST which has been used for over half a century.
 
 
Resource | Tools
The monitoring tool is divided into two parts. The first part addresses epidemiological trends in mother-to-child transmission in prison, with a view to collecting the epidemiological data needed to monitor progress towards the global targets on prevention of mother-to-child transmission. The second part covers access to health care and social services needed within the prison setting in order to reach the 2025 HIV targets. Indicators in this second part include information on the availability and coverage of relevant services. Public health-care priorities as set in the UNODC technical guidance documents are taken into consideration, as is the protection of human rights, women’s rights, privacy and confidentiality.  
 
 
Resource | Guidelines
In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at reducing the risk of HIV acquisition. This guideline provides implementation considerations to support Member States, programme managers, policy makers, researchers, health workers, communities, and other stakeholders in the implementation of projects and programmes for CAB-LA. It also outlines critical research gaps for CAB-LA.
 
 
Resource | Guidelines
The Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations outline a public health response for 5 key populations (men who have sex with men, trans and gender diverse people, sex workers, people who inject drugs and people in prisons and other closed settings). They present and discuss new recommendations and consolidate a range of recommendations and guidance from current WHO guidelines. Particularly for key populations, social, legal, structural and other contextual factors both increase vulnerability to HIV, viral hepatitis and STIs and obstruct access to health and other essential services. These guidelines highlight the critical importance of addressing structural barriers in all settings as a priority.
 
 
Resource | Guidelines
These guidelines focus on the collection and use of person-centred data across the HIV cascade – from prevention, testing and treatment to longer-term health care – building upon 2017 and 2020 strategic information guidelines. The updated guidelines present a standard minimum dataset, priority indicators and recommendations to strengthen data use across HIV prevention, testing and treatment, and linkages to services for sexually transmitted infections, viral hepatitis, tuberculosis and cervical cancer. The guidelines also cover the use of routinely collected data for HIV surveillance (including measurement of HIV prevalence and incidence) and emphasize the use of data from different sources to gain a better picture of epidemiologic trends.